C43

Cosmo confirms full redemption in cash of €175m Convertible Bonds

Retrieved on: 
Jeudi, décembre 14, 2023
C43, XETRA, Security (finance)

Dublin, Ireland – 06 December 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it has fully redeemed all of its EUR 175 million 2.5% Senior Unsecured Convertible Bonds due 2023 in cash.

Key Points: 

Dublin, Ireland – 06 December 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it has fully redeemed all of its EUR 175 million 2.5% Senior Unsecured Convertible Bonds due 2023 in cash.

Cosmo announces submission of Winlevi® to the European Medicines Agency (EMA)

Retrieved on: 
Mardi, octobre 17, 2023
III, European, Prescription, IQVIA, Cosmo, Ageing, Safety, Sun Pharma, EMA, FDA, Marketing Authorisation Application, European Medicines Agency, Marketing, IGA, Acne, XETRA, Dermatology, Patient, C43, MAA, Pharmaceutical industry, Medical device, EU

This filing marks a significant milestone in pipeline progression, as approval will open the substantial EU market to already selected, high-standing partners.

Key Points: 
  • This filing marks a significant milestone in pipeline progression, as approval will open the substantial EU market to already selected, high-standing partners.
  • Cosmo has officially submitted the Marketing Authorisation Application (MAA) for its innovative acne treatment clascoterone 1% cream (Winlevi®) to the European Medicine Agency (EMA) through the centralized procedure, aimed at obtaining a single Marketing Authorization for the product in the European Union.
  • The EMA's rigorous evaluation process will assess the product's safety, quality, and efficacy, ultimately determining its suitability for approval within the European market.
  • This submission to the EMA is a pivotal step forward in our mission as well as a testament to our ongoing commitment to innovation.

Cosmo and Hikma Sign License Agreement for Winlevi® in 17 Middle Eastern and North African Countries

Retrieved on: 
Lundi, octobre 2, 2023
LSE, IQVIA, African, XETRA, Clascoterone, Acne, Sun Pharma, Prescription, USD, Dermatology, C43, Patient, OTC, Ageing, Kingdom, FDA, Nasdaq Dubai, Health, Skin, Pharmaceutical industry, Cassiopea

Under the terms of the agreement, Hikma will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to register and commercialize Winlevi® in 17 Middle Eastern and North African countries.

Key Points: 
  • Under the terms of the agreement, Hikma will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to register and commercialize Winlevi® in 17 Middle Eastern and North African countries.
  • Cassiopea will receive an upfront payment of USD 750,000 in addition to potential regulatory and sales milestones.
  • Cassiopea will be the exclusive supplier of the product at a price calculated on the net sales.
  • Over 15,000 US health care providers have prescribed Winlevi® to date which represents 88% of total health care providers in dermatology.

Cosmo and Glenmark announce the signing of Distribution and License Agreements for Winlevi® in Europe and South Africa

Retrieved on: 
Mercredi, septembre 27, 2023
Acne, Harrogate and District NHS Foundation Trust, Prevalence, Czech Republic, Glenmark, IQVIA, European Medicines Agency, XETRA, Prescription, Centralisation, Inflammation, USD, EMA, U.S. FDA, Gland, Dermatology, King Hamad University of Nursing and Associated Medical Sciences, C43, Patient, Risk, Sebaceous gland, Ageing, Research, Skin, Pharmaceutical industry, EU, Cassiopea, Clascoterone

MUMBAI, India and DUBLIN, Sept. 27, 2023 /PRNewswire/ --  Cosmo Pharmaceuticals N.V. (SIX: COPN), (XETRA: C43) ("Cosmo") and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. ("Glenmark"), today announced the signing of distribution and license agreements for Winlevi® (clascoterone cream 1%) in Europe and South Africa.

Key Points: 
  • MUMBAI, India and DUBLIN, Sept. 27, 2023 /PRNewswire/ --  Cosmo Pharmaceuticals N.V. (SIX: COPN), (XETRA: C43) ("Cosmo") and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. ("Glenmark"), today announced the signing of distribution and license agreements for Winlevi® (clascoterone cream 1%) in Europe and South Africa.
  • Alessandro Della Chà, CEO of Cosmo, said, "We are very pleased to partner with Glenmark.
  • Their strong expertise in the commercialization of pharmaceutical compounds gives us great confidence in their ability to successfully market Winlevi®.
  • Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements.

Cosmo and Glenmark announce the signing of Distribution and License Agreements for Winlevi® in Europe and South Africa

Retrieved on: 
Mercredi, septembre 27, 2023
Acne, Harrogate and District NHS Foundation Trust, Prevalence, Czech Republic, Glenmark, IQVIA, European Medicines Agency, XETRA, Prescription, Centralisation, Inflammation, USD, EMA, U.S. FDA, Gland, Dermatology, King Hamad University of Nursing and Associated Medical Sciences, C43, Patient, Risk, Sebaceous gland, Ageing, Research, Skin, Pharmaceutical industry, EU, Cassiopea, Clascoterone

MUMBAI, India and DUBLIN, Sept. 27, 2023 /PRNewswire/ --  Cosmo Pharmaceuticals N.V. (SIX: COPN), (XETRA: C43) ("Cosmo") and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. ("Glenmark"), today announced the signing of distribution and license agreements for Winlevi® (clascoterone cream 1%) in Europe and South Africa.

Key Points: 
  • MUMBAI, India and DUBLIN, Sept. 27, 2023 /PRNewswire/ --  Cosmo Pharmaceuticals N.V. (SIX: COPN), (XETRA: C43) ("Cosmo") and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. ("Glenmark"), today announced the signing of distribution and license agreements for Winlevi® (clascoterone cream 1%) in Europe and South Africa.
  • Alessandro Della Chà, CEO of Cosmo, said, "We are very pleased to partner with Glenmark.
  • Their strong expertise in the commercialization of pharmaceutical compounds gives us great confidence in their ability to successfully market Winlevi®.
  • Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements.

Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma

Retrieved on: 
Lundi, septembre 4, 2023
Agreement, Diarrhea, XETRA, Traveler, C43, MMX, Growth, Bacteria, Pharmaceutical industry, EU

Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma

Key Points: 
  • Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma
    Dublin, Ireland – 4 September 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the termination by mutual agreement of the license with Dr. Falk Pharma for Rifamycin SV MMX® in the EU and other selective countries.
  • Rifamycin SV MMX® is an orally administered, delayed-release, non-systemic antibiotic approved for the treatment of Travelers' Diarrhea caused by certain bacteria.
  • It is the first antibiotic engineered with Cosmo’s proprietary Multi Matrix Technology (MMX®).
  • MMX technology is designed to deliver the active pharmaceutical ingredients in a delayed and controlled manner directly to the lower intestine.

Cosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg in Europe, APAC, MENA and LATAM regions

Retrieved on: 
Lundi, septembre 4, 2023
Partnership, Diarrhea, XETRA, Traveler, C43, Patient, MMX, Growth, Bacteria, MENA, Airline, Pharmaceutical industry, EU, LATAM

Cosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg in Europe, APAC, MENA and LATAM regions

Key Points: 
  • Cosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg in Europe, APAC, MENA and LATAM regions
    Dublin, Ireland – 4 September 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Adalvo Ltd. (“Adalvo”) today announced the signing of a license and supply agreement for Rifamycin SV with MMX® technology in Europe, Asia-Pacific (APAC), Middle East/North Africa (MENA) and Latin America (LATAM) regions.
  • Under the terms of the agreement, Adalvo will receive from Cosmo the exclusive right to develop, register and commercialize Rifamycin SV MMX® 200mg in these respective regions.
  • Cosmo will receive an upfront payment in addition to potential regulatory and sales milestones and customary double-digit royalties on net sales.
  • Rifamycin SV MMX® is an orally administered, delayed-release, non-systemic antibiotic approved for the treatment of Travelers' Diarrhea caused by certain bacteria.

Cosmo announces Cortiment® approval in Japan

Retrieved on: 
Mercredi, juin 28, 2023
Budesonide, Ferring Pharmaceuticals, Bleeding, Prevalence, IBD, Medicines and Healthcare products Regulatory Agency, Bausch, Weight loss, Quality of life, XETRA, Cramp, Inflammation, Diarrhea, Colon, Tablet, Inflammatory bowel disease, Defecation, C43, UC, Cosmo, Ulcerative colitis, PMDA, MMX, Bloating, Ulcer, Fatigue, Pharmaceutical industry

Dublin, Ireland – 28 June 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its partner Ferring Pharmaceuticals (“Ferring”) has received the approval for Cortiment® (budesonide 9 mg MMX tablets) in Japan by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).

Key Points: 
  • Dublin, Ireland – 28 June 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its partner Ferring Pharmaceuticals (“Ferring”) has received the approval for Cortiment® (budesonide 9 mg MMX tablets) in Japan by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
  • First sales of Cortiment® in Japan are expected to begin by end of Q3 2023.
  • Cortiment® has been developed by Cosmo and is globally distributed by Ferring, with the exception of the US, where it is distributed by Bausch.
  • Alessandro Della Chà, CEO of Cosmo Pharmaceuticals, comments: “We are very pleased with the new success our partner Ferring Pharmaceuticals has achieved with Cortiment®.

Cosmo and Hyundai Pharm Announce Signing of License Agreement for Winlevi® in Korea

Retrieved on: 
Jeudi, juin 22, 2023
National health insurance, Male, Partnership, Androgen, IQVIA, Pharming, Quality of life, XETRA, Clascoterone, Hira, Sun Pharma, Acne, Prescription, Incidence, Spironolactone, C43, Hyundai, Patient, Physician, South Korea, Health Insurance Review and Assessment Service, License, Ageing, FDA, Skin, HIRA, Female, Pharmaceutical industry, Cassiopea

Dublin, Ireland & Seoul, Korea – 22 June 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hyundai Pharmaceutical Co., Ltd. (“Hyundai Pharm”) today announced the signing of a License Agreement for Winlevi® (clascoterone) cream 1% in the Republic of Korea.

Key Points: 
  • Dublin, Ireland & Seoul, Korea – 22 June 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hyundai Pharmaceutical Co., Ltd. (“Hyundai Pharm”) today announced the signing of a License Agreement for Winlevi® (clascoterone) cream 1% in the Republic of Korea.
  • Under the terms of the agreement, Hyundai Pharm will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to register and commercialize Winlevi® in the Republic of Korea.
  • With this license agreement, Hyundai Pharm aims to address this unmet medical need by offering a new treatment option for both male and female acne patients in South Korea.
  • SangJoon Lee, Chief Executive Officer of Hyundai Pharm, said “We are delighted to establish a strategic partnership through the licensing agreement with Cosmo and its subsidiary, Cassiopea.

Cosmo Pharmaceuticals announces approval of Winlevi® in Canada

Retrieved on: 
Mardi, juin 20, 2023
BSE, Reuters, Depression, Anxiety, Health, Dermatology, Sun, XETRA, Clascoterone, Acne, Sun Pharma, NSE, C43, Patient, Risk, Health Canada, Pharmaceutical industry

Dublin, Ireland – 20 June 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its partner Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (“Sun Pharma”) has received marketing authorization (“Notice of Compliance”) from Health Canada for Winlevi® (clascoterone cream 1%).

Key Points: 
  • Dublin, Ireland – 20 June 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its partner Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (“Sun Pharma”) has received marketing authorization (“Notice of Compliance”) from Health Canada for Winlevi® (clascoterone cream 1%).
  • Diana Harbort, President of the Dermatology Division of Cosmo, said: “We are very pleased with this success our partner Sun Pharma achieved once again with Winlevi®.
  • This is another major achievement in the mission of Cosmo and Sun Pharma to improve the lives of patients affected by skin conditions”.
  • Data shows that acne affects patients’ health-related quality of life and may increase the risk of depression and anxiety.